JPH11514879A - 原始ヒト幹細胞を有するMp1リガンドの使用法 - Google Patents
原始ヒト幹細胞を有するMp1リガンドの使用法Info
- Publication number
- JPH11514879A JPH11514879A JP9517062A JP51706297A JPH11514879A JP H11514879 A JPH11514879 A JP H11514879A JP 9517062 A JP9517062 A JP 9517062A JP 51706297 A JP51706297 A JP 51706297A JP H11514879 A JPH11514879 A JP H11514879A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- thrombopoietin
- cell
- lin
- stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.骨髄増殖性受容体(mpl)リガンドの存在下幹細胞を培養し、該リガンド をmplに結合させてmpl−介在生物活性を起こすことを含む、培養中の幹細 胞の生存を促進する方法。 2.該mplリガンドがトロンボポエチンである、請求の範囲第1項に記載の 方法。 3.該トロンボポエチンがヒトトロンボポエチンである、請求の範囲第2項に 記載の方法。 4.該トロンボポエチンが組換えヒトトロンボポエチンである、請求の範囲第 3項に記載の方法。 5.該mplリガンドの存在下で培養される該細胞が、自己再生能および全て の造血細胞系列を生ぜしめる能力を特徴とする、請求の範囲第1項に記載の方法 。 6.該細胞がヒト幹細胞である、請求の範囲第1項に記載の方法。 7.該細胞がCD34+である、請求の範囲第6項に記載の方法。 8.該細胞がCD34+Thy−1+である、請求の範囲第6項に記載の方法。 9.該細胞がCD34+Lin-である、請求の範囲第6項に記載の方法。 10.該細胞がCD34+Thy+Lin-である、請求の範囲第6項に記載の方法。 11.該細胞がCD34++Lin-RholoまたはCD34+Thy+Lin-Rholoであ る、請求の範囲第6項に記載の方法。 12.該組換えヒトトロンボポエチンが約1ng/mlから約100ng/mlの濃度で 存在する、請求の範囲第4項に記載の方法。 13.幹細胞をmplリガンドにさらし、幹細胞を増殖させて幹細胞の拡張集団 を形成すること含む、幹細胞の集団を拡張する方法。 14.該mplリガンドがトロンボポエチンである、請求の範囲第13項に記載 の方法。 15.該トロンボポエチンがヒトトロンボポエチンである、請求の範囲第14項 に記載の方法。 16.該トロンボポエチンが組換えヒトトロンボポエチンである、請求の範囲第 15項に記載の方法。 17.該拡張細胞は、実質的な自己再生を受ける能力および全ての造血細胞系列 を生ぜしめる能力を特徴とする、請求の範囲第13項に記載の方法。 18.該細胞がヒト幹細胞である、請求の範囲第13項に記載の方法。 19.該細胞がCD34+である、請求の範囲第18項に記載の方法。 20.該細胞がCD34+Lin-である、請求の範囲第19項に記載の方法。 21.該細胞がCD34+Thy−1+である、請求の範囲第19項に記載の方法。 22.該細胞がCD34+Thy+Lin-である、請求の範囲第19項に記載の方法 。 23.該細胞がCD34+Lin-RholoまたはCD34+Thy+Lin-Rholoである 、請求の範囲第19項に記載の方法。 24.該組換えヒトトロンボポエチンが約1ng/mlから約100ng/mlの濃度で 存在する、請求の範囲第16項に記載の方法。 25.ヒト対象に造血能力を回復させるための治療法であって: (a)ヒト対象から幹細胞を摘出し、 (b)該細胞をmplリガンドの存在下で拡張させて、ヒト対象から拡張幹細胞 集団を形成し;そして、 (c)該拡張細胞を該対象に戻して、造血能力を該対象に回復させる、 工程を含む、方法。 26.該拡張幹細胞集団は、自己再生能および全ての造血細胞系列を生ぜしめる 能力を特徴とする、請求の範囲第25項に記載の方法。 27.該mplリガンドがトロンボポエチンである、請求の範囲第25項に記載 の方法。 28.該トロンボポエチンがヒトトロンボポエチンである、請求の範囲第25項 に記載の方法。 29.該トロンボポエチンが組換えヒトトロンボポエチンである、請求の範囲第 28項に記載の方法。 30.該組換えヒトトロンボポエチンが約1ng/mlから約100ng/mlの濃度で 存在する、請求の範囲第29項に記載の方法。 31.該細胞を更に1種以上のサイトカイン類の存在下で拡張させる、請求の範 囲第25項に記載の方法。 32.該サイトカインが、インターロイキン3(IL−3)、インターロイキン6 (IL−6)、白血病阻害因子(LIF)、c−kitリカンド(KL)、顆粒球−マクロ ファージコロニー刺激因子(GM−CSF)、顆粒球コロニー刺激因子(G−CS F)およびスチール因子(Stl)からなる群から選択される、請求の範囲第31項 に記載の方法。 33.該サイトカインまたは該サイトカイン類の1種がIL−3である、請求の 範囲第32項に記載の方法。 34.静止幹細胞をmplリガンドにさらして、該細胞を活性化して分裂させる ことを含む、静止幹細胞を分裂させるために活性化する方法。 35.該mplリガンドがトロンボポエチンである、請求の範囲第34項に記載 の方法。 36.該トロンボポエチンがヒトトロンボポエチンである、請求の範囲第35項 に記載の方法。 37.該トロンボポエチンが組換えヒトトロンボポエチンである、請求の範囲第 36項に記載の方法。 38.該細胞がヒト幹細胞である、請求の範囲第34項に記載の方法。 39.該細胞がCD34+である、請求の範囲第38項に記載の方法。 40.該細胞がCD34+Lin-である、請求の範囲第38項に記載の方法。 41.該細胞がCD34+Thy−1+である、請求の範囲第38項に記載の方法。 42.該細胞がCD34+Thy+Lin-である、請求の範囲第38項に記載の方法 。 43.該細胞がCD34+Lin-RholoまたはCD34+Thy+Lin-Rholoである 、請求の範囲第38項に記載の方法。 44.該活性細胞から形成された細胞は、自己再生能および全ての造血細胞系列 を生ぜしめる能力を特徴とする、請求の範囲第34項に記載の方法。 45.該組換えヒトトロンボポエチンが約1ng/mlから約100ng/mlの濃度で 存在する、請求の範囲第37項に記載の方法。 46.幹細胞を修飾する方法であって; (a)外来遺伝子をウイルスベクターへ挿入し; (b)静止幹細胞をmplリガンドの存在下で培養して、該細胞を活性化して分 裂させ;そして、 (c)該活性化細胞を該ウイルスベクターにさらして、該外来遺伝子を該幹細胞 のDNAへ挿入する、 工程を含む、方法。 47.該mplリガンドがトロンボポエチンである、請求の範囲第46項に記載 の方法。 48.該トロンボポエチンがヒトトロンボポエチンである、請求の範囲第47項 に記載の方法。 49.該トロンボポエチンが組換えヒトトロンボポエチンである、請求の範囲第 48項に記載の方法。 50.対象に遺伝子治療を提供する方法であって、 (a)外来遺伝子をウイルスベクターに挿入し; (b)静止幹細胞をmplリガンドの存在下で培養して、該細胞を活性化して分 裂させ; (c)該活性化細胞を該ウイルスベクターにさらして、該外来遺伝子を該幹細胞 のDNAに組込み;そして、 (d)そのようにして修飾した該幹細胞を、これを必要とする対象に提供する、 ことを含む、。 51.該外来遺伝子がmdr1遺伝子産物、アデノシンデアミナーゼ、グルコセ レブロシダーゼ、β−グロブリン、VIII因子、IX因子、mdr関連タンパク 質、T−細胞受容体、サイトカイン、およびHIVの複製を妨げるタンパク質か らなる群から選択されるタンパク質をコードする、請求の範囲第46項に記載の 方法。 52.該外来遺伝子がアンチセンスまたはリボザイム配列である、請求の範囲第 46項に記載の方法。 53.幹細胞の培養法におけるmplリガンドの使用。 54.mplリガンドがトロンボポエチンである、請求の範囲第53項に記載の 使用。 55.幹細胞がCD34+細胞である、請求の範囲第53項または第54項に記 載の使用。 56.遺伝子治療または造血再構成に使用する細胞組成物の製造におけるmpl リガンドの使用。 57.mplリガンドおよび1種以上のサイトカインを含む細胞培養培地。 58.トロンボポエチン10〜200mg/mlおよびIL−3 1〜100ng/ml を含む、請求の範囲第57項に記載の細胞培養培地。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/550,167 | 1995-10-30 | ||
US08/550,167 US6060052A (en) | 1995-10-30 | 1995-10-30 | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
PCT/EP1996/004698 WO1997016535A2 (en) | 1995-10-30 | 1996-10-29 | METHODS FOR USE OF Mpl LIGANDS WITH PRIMITIVE HUMAN STEM CELLS |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11514879A true JPH11514879A (ja) | 1999-12-21 |
Family
ID=24196022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9517062A Pending JPH11514879A (ja) | 1995-10-30 | 1996-10-29 | 原始ヒト幹細胞を有するMp1リガンドの使用法 |
Country Status (6)
Country | Link |
---|---|
US (4) | US6060052A (ja) |
EP (1) | EP0858503A1 (ja) |
JP (1) | JPH11514879A (ja) |
AU (1) | AU717783B2 (ja) |
CA (1) | CA2236263C (ja) |
WO (1) | WO1997016535A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023028035A1 (en) * | 2021-08-23 | 2023-03-02 | University Of Florida Research Foundation, Incorporated | Lipid enveloped recombinant aav particles for gene therapy use |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1293827B1 (it) * | 1997-08-07 | 1999-03-10 | Dompe Spa | Metodo per l'espansione ex vivo di cellule staminali emopoietiche |
WO1999011262A1 (en) * | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
US6429012B1 (en) * | 1997-10-06 | 2002-08-06 | Viacell, Inc. | Cell population containing non-fetal hemangioblasts and method for producing same |
CA2318819A1 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Expanded and genetically modified populations of human hematopoietic stem cells |
AU2002301459B2 (en) * | 1998-02-05 | 2004-11-25 | Novartis Ag | Expanded and genetically modified populations of human hematopoietic stem cells |
AU4214799A (en) * | 1998-05-28 | 1999-12-13 | St. Jude Children's Research Hospital | Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof |
US7622557B2 (en) | 1998-05-28 | 2009-11-24 | St. Jude Children's Research Hospital | Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP) |
CA2346152A1 (en) * | 1998-10-16 | 2000-04-27 | Novartis Ag | Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors |
ATE284220T1 (de) | 1999-02-03 | 2004-12-15 | Idm Immuno Designed Molecules | Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode |
KR100399134B1 (ko) * | 2000-07-27 | 2003-09-26 | 삼성전자주식회사 | 전자렌지 |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
AU2003275077B2 (en) * | 2002-09-18 | 2010-02-04 | Ortho-Mcneil Pharmaceutical, Inc. | Methods of increasing platelet and hematopoietic stem cell production |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
AU2004320466A1 (en) * | 2003-06-11 | 2006-02-02 | Jan Remmereit | Nuclear reprogramming of cells for therapeutic use |
US7723295B2 (en) * | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
RS56387B1 (sr) * | 2003-08-28 | 2017-12-29 | Ortho Mcneil Pharm Inc | Peptidi i jedinjenja koja se vežu za trombopoetinski receptor |
US20050265980A1 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
JP2008505650A (ja) * | 2004-07-12 | 2008-02-28 | ソリン・グループ・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータ | ヒト細胞を増殖させるための装置及び方法 |
US20060210542A1 (en) * | 2004-08-16 | 2006-09-21 | Yurkow Edward J | Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
WO2007108559A1 (ja) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
WO2009072635A1 (ja) * | 2007-12-06 | 2009-06-11 | Nissan Chemical Industries, Ltd. | ヘテロ環化合物による造血幹細胞の増幅方法 |
BRPI1014635A8 (pt) | 2009-06-04 | 2016-10-11 | Nissan Chemical Ind Ltd | compostos heterocíclicos e agentes de expansão para células-tronco hematopoiéticas |
CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
US10869898B2 (en) | 2014-04-01 | 2020-12-22 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714680B1 (en) * | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5147784A (en) * | 1990-04-12 | 1992-09-15 | Systemix, Inc. | T-lymphocyte progenitor cell assay |
DE4041753A1 (de) | 1990-12-24 | 1992-06-25 | Henkel Kgaa | Neue reaktivkontaktkleber, verfahren zu ihrer herstellung und ihre verwendung |
WO1995003693A1 (en) * | 1993-07-29 | 1995-02-09 | Systemix, Inc. | Novel stem cell marker |
NZ281482A (en) * | 1994-02-14 | 2000-09-29 | Univ Washington | The stimulation of erythropoiesis using thrombopoietin and erythropoietin |
NZ271230A (en) * | 1994-02-14 | 1998-03-25 | Zymogenetics Inc | Hematopoietic proteins, production and use |
US5728581A (en) * | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
-
1995
- 1995-10-30 US US08/550,167 patent/US6060052A/en not_active Expired - Lifetime
-
1996
- 1996-10-29 EP EP96937284A patent/EP0858503A1/en not_active Withdrawn
- 1996-10-29 CA CA002236263A patent/CA2236263C/en not_active Expired - Lifetime
- 1996-10-29 AU AU74953/96A patent/AU717783B2/en not_active Ceased
- 1996-10-29 WO PCT/EP1996/004698 patent/WO1997016535A2/en active Application Filing
- 1996-10-29 JP JP9517062A patent/JPH11514879A/ja active Pending
-
1999
- 1999-06-08 US US09/328,188 patent/US6326205B1/en not_active Expired - Lifetime
-
2001
- 2001-10-22 US US10/052,879 patent/US6916470B2/en not_active Expired - Fee Related
-
2005
- 2005-07-01 US US11/173,431 patent/US7416887B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023028035A1 (en) * | 2021-08-23 | 2023-03-02 | University Of Florida Research Foundation, Incorporated | Lipid enveloped recombinant aav particles for gene therapy use |
Also Published As
Publication number | Publication date |
---|---|
US7416887B2 (en) | 2008-08-26 |
EP0858503A1 (en) | 1998-08-19 |
AU7495396A (en) | 1997-05-22 |
CA2236263C (en) | 2009-01-20 |
CA2236263A1 (en) | 1997-05-09 |
WO1997016535A2 (en) | 1997-05-09 |
US20060024275A1 (en) | 2006-02-02 |
US20030082805A1 (en) | 2003-05-01 |
US6916470B2 (en) | 2005-07-12 |
AU717783B2 (en) | 2000-03-30 |
US6060052A (en) | 2000-05-09 |
WO1997016535A3 (en) | 1997-08-28 |
US6326205B1 (en) | 2001-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7416887B2 (en) | Methods for use of MPL ligands with primitive human stem cells | |
US6586192B1 (en) | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals | |
US5681559A (en) | Method for producing a highly enriched population of hematopoietic stem cells | |
US5821108A (en) | Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker | |
US20040106195A1 (en) | Method for identification of cell growth or differentiation factors | |
JP2010525836A (ja) | ヒト造血幹細胞のexvivo増殖 | |
WO1996015228A1 (en) | Method of purifying a population of cells enriched for hematopoietic stem cells | |
JP2002527101A (ja) | ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進 | |
EP1053302B1 (en) | Expanded and genetically modified populations of human hematopoietic stem cells | |
JP2002543829A (ja) | 哺乳動物造血幹細胞のexvivoでの増殖 | |
JP2002503942A (ja) | 体外での細胞培養及び移植用キット | |
Valtieri et al. | Efficient transfer of selectable and membrane reporter genes in hematopoietic progenitor and stem cells purified from human peripheral blood | |
US20030100107A1 (en) | Compositions and methods for generating differentiated human cells | |
CA2307624A1 (en) | Hematopoietic stem cells | |
US20120201792A1 (en) | Methods and products for manipulating hematopoietic stem cells | |
US20040265995A1 (en) | sFRP1 and uses thereof | |
WO1996015227A1 (en) | Methods of inducing cell death of primitive hematopoietic cells and compositions for induction thereof | |
Berson et al. | Selection of murine lymphoid and hematopoietic cells using polystyrene tissue culture devices containing covalently immobilized antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061017 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070112 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070626 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071024 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071225 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080117 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100120 |